Sign in Subscribe

Archive

A collection of 715 issues

Latest

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is

Multi-cancer blood tests may not match colonoscopy for colorectal cancer prevention

Skip to content The CRC Digest ▪ SCREENING Multi-cancer blood tests may not match colonoscopy for colorectal cancer prevention A modeling study found that multi-cancer early detection blood tests offer little opportunity for cancer prevention through precursor lesion removal, raising questions about whether detecting multiple cancers can offset the loss of

Blood-based surveillance after surgery increased curative treatment for recurrence

Skip to content The CRC Digest ▪ SCREENING Blood-based surveillance after surgery increased curative treatment for recurrence The phase III FIND trial showed that ctDNA methylation-guided surveillance in nonmetastatic colorectal cancer patients after surgery led to higher rates of curative-intent therapy for recurrence compared to standard CT-based monitoring. (Journal of Clinical

Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to

CRC Research Update — July 28, 2026

Today's colorectal cancer research highlights

Review Examines Resistance Mechanisms to Anti-EGFR Therapies

Skip to content The CRC Digest Review Examines Resistance Mechanisms to Anti-EGFR Therapies A review of cetuximab and panitumumab resistance found that intrinsic resistance often stems from pre-existing KRAS, NRAS, and BRAF mutations, while acquired resistance develops through clonal evolution under therapeutic pressure. (Pharmaceuticals) This content is informational only and

Immunotherapy May Reshape Fertility Counseling for Young Women with CRC

Skip to content The CRC Digest Immunotherapy May Reshape Fertility Counseling for Young Women with CRC A narrative review found that immune checkpoint inhibitors for dMMR/MSI-H colorectal cancer may affect reproductive-age women through direct reproductive uncertainty (including endocrine toxicities and hypothesized, but currently unproven, direct gonadal effects) and potential

Canadian Symposium Highlights Care Gaps for Early-Onset Cancer Patients

Skip to content The CRC Digest Canadian Symposium Highlights Care Gaps for Early-Onset Cancer Patients The 2025 Early Age Onset Cancer Symposium identified critical gaps including diagnostic delays, screening eligibility criteria that no longer reflect current disease epidemiology, and insufficient age-appropriate infrastructure for patients under 50. (Curr Oncol) This content

Polyp Risk Rises with Age in Young Adults, Study Finds

Skip to content The CRC Digest Polyp Risk Rises with Age in Young Adults, Study Finds A retrospective colonoscopy study of 3,959 adults aged 18-44 used Joinpoint regression to identify age inflection points for polyp detection rates, with detection rates for polyps, adenomas, and serrated lesions all rising significantly

Updated Guidelines for Resectable Colorectal Cancer Published

Skip to content The CRC Digest ● REGULATORY Updated Guidelines for Resectable Colorectal Cancer Published The American Society of Surgical Oncology summarized contemporary guidance from NCCN, ESMO, and JSCCR, highlighting recent evolution in molecular characterization (including mismatch repair status), neoadjuvant therapy, and organ-preservation strategies. (Ann Surg Oncol) This content is informational